Recent Finacing
Recent Raise
Aptadel Therapeutics is a biotechnology company developing ApDC conjugates and the lead candidate ADEL‑101 to target Ewing sarcoma.
Focus Areas
Recent Investors
Total Raised
Funding round
See the team members at Aptadel Therapeutics.
